Advances in Alzheimer’s Disease Drug Development

Table 1 Selected Alzheimer’s disease drug development programs

Drug	Mechanism of action	Phase of development	Stage of disease
Solanezumab	Aβ – Passive Immunization	III	PRE, MD
Crenezumab	Aβ – Passive Immunization	II	PRE, MD
BIIB-037	Aβ – Passive Immunization	III	PRO, MD
ACI-Anti-Tau Ab	Tau – Passive Immunization	I	MMD
MK-8931	BACE Inhibition	II/III	PRO, MD
ACC-001	Aβ – Active Immunization	II	MMD
ACI-24	Aβ – Active Immunization	II	MMD
CAD-106	Aβ – Active Immunization	II	MMD
ACI-35	Tau – Active Immunization	I	MMD
ACI-24	Tau – Active Immunization	II	MMD
NGF	Neuroprotectant	II	MMD
TTP-488	RAGE Inhibitor	III	MMD
EVP-6124	Cholinergic agonist	II	MMD
AZD0530	Fyn kinase inhibitor	II	MD
Pioglitazone	PPAR-γ agonist	III	PRE

Aβ, Beta-amyloid; BACE, Beta-secretase cleaving enzyme; MD, Mild dementia; MMD, Mild to Moderate Dementia; NGF, Nerve growth factor; PPAR-γ, Peroxisome-proliferator activated receptor γ; PRE, Preclinical; PRO, Prodromal; RAGE, Receptor for advanced glycation end-products.

ISSN: 1741-7015